A leading biotech company in UK, the Native Antigen Company yesterday announced the commercial introduction of its lab synthesized Covid-19 coronavirus
antigens, derived from the emerging Wuhan coronavirus
The synthesized recombinant proteins offer scientists high-quality reagents to support ongoing infectious disease research, and the development of diagnostics and vaccines, says the Oxford, British-based company.
The accredited biotech Native Antigen Company has developed rapid response manufacturing capabilities to produce reagents for emerging epidemic diseases according to the World Health Organization's R&D Blueprint, which urges the accelerated development of vaccines and the increased availability of accurate and reliable diagnostics for priority emerging infectious diseases.
These lab synthesized antigens have been derived specifically from the newly identified new coronavirus (Covid-19
) using The Native Antigen Company’s proprietary mammalian, VirtuE expression system.
This protein synthesizing system is able to introduce proper protein folding and post-translational modifications to recombinant proteins, which are essential for full biological and antigenic activity.
The firm’s commercial director Dr Andy Lane told Thailand Medical News
via a phone interview, “Our mission is to reduce the global burden of infectious disease by developing the highest-quality reagents in rapid response to emerging public health threats. The release of these Coronavirus
antigens within one month of the newly identified Covid-19
genome being published exemplifies the power of The Native Antigen Company’s recombinant protein platforms to prepare reagents in response to new threats,”
He further added, “As one of the first recognized suppliers to release Covid-19 coronavirus
proteins, we are proud to be able to offer these antigens to in vitro diagnostics and pharmaceutical researchers to help drive the development of serological assays and vaccines that will be vital in stemming the spread of this disease.”
Antigens such as these are useful for the development of diagnostics reagents and platforms especially more so now that it has been emerging that there has been so much flaws and blunders in the diagnostics of the coronavirus to date.
As the reported death toll from the novel coronavirus
passes 1,370 out of more than 60,670 known cases, it is becoming critical that diagnostics, treatment and vaccine protocols come into place as quickly as possible.
For reliable and fast updates on the coronavirus
developments of about Thailand Coronavirus
Scenes, check out https://www.thailandmedical.news/articles/coronavirus